1. Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate. Roberto AlfonsoAccinelli et al. ELSEVIER. 14 september, 2021.
  2. Myocarditis After BNT162b2 and mRNA-1273 Vaccination. Kathryn F. Larson, et al. AHA Journals. June 16, 2021. https://doi.org/10.1161/CIRCULATIONAHA.121.055913
  3. The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. Asiya Kamber Zaidi y Puya Dehgani-Mobaraki. Nature. June 15, 2021.
  4. Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection. Curt J. Daniels, MD et al. JAMA Cardiology. May 27, 2021.
  5. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Obbina Abani et al. THE LANCET. May 01, 2021.
  6. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Sanjay Ramakrishnan et al. The Lancet. April 09, 2021.
  7. Post-COVID-19 paediatric inflammatory multisystem syndrome: association of ethnicity, key worker and socioeconomic status with risk and severity. Jonathan Broad et al. BMJ Journals. March 16, 2021. 
  8. Global trends in clinical studies of ivermectin in COVID-19. Morimasa Yagisawa et al. THE JAPANESE JOURNAL OF ANTIBIOTICS. March 10, 2021.
  9. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. Kerri L LaRovere et al. JAMA Neurology. March 05, 2021.
  10. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial. Eduardo López-Medina et al. JAMA Network. March 04, 2021. 
  11. The role of C-reactive protein as a prognostic marker in COVID-19. Dominic Stringer et al. International Journal of Epidemiology. March 03, 2021. 
  12. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. Carlos Chaccour et al. EClinicalMedicine. February 01, 2021.
  13. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.  C. Garrett Rappazzo et al. Science. Januay 25, 2021. 
  14. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Andrew Hill, Ahmed Abdulamir et al. Research Square. January 19, 2021. 
  15. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. Sheila F. Lumley et al. The New England Journal of Medicine. December 23, 2020. 
  16. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Gemma E. Hartley et al. ScienceImmunology. December 22, 2020. 
  17. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Robert M. Cox, Josef D. Wolf & Richard K. Plemper. December 03, 2020. 
  18. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Petra Zimmermann, Nigel Curtis. Archives of Disease in Childhood. December 01, 2020. 
  19. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. R.Torres-Castro et al. ScienceDirect. November 25, 2020. 
  20. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. Biswa Mohan Padhy et al. J Pharm Pharm Sci. November 23, 2020. 
  21. Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. Gregory Piazza, MD, MS1; David A. Morrow, MD, MPH. JAMA Network. November 23, 2020. 
  22. Comprehensive health assessment three months after recovery from acute COVID-19. Bram van den Borst, MD, PhD et al. Clinical Infectious Diseases. November 21, 2020. 
  23. Study of the Efficacy and Safety of Topical Ivermectin + Iota- Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. Carvallo, Hector. Journal of Biomedical Research and Clinical Investigation. 20 noviembre del 2020. 
  24. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Shiyi Cao et al. Nature Commnunications. November 20, 2020. 
  25. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Sabrina Setembre Batah and Alexandre Todorovic Fabro. Elsevier. November 19, 2020. 
  26. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study. Perry RJ et al. BMJ Jounals. November 05, 2020. 
  27. How COVID-19 has affected emergent visits to a Latin-American trauma department: Experience at a Peruvian national trauma referral center. Juan F. Pintado, et al. International Journal of the Care of the Injured. November 02, 2020. 
  28. The Role of Vitamin D in The Age of COVID-19: A Systematic Review and Meta-Analysis. View ORCID ProfileRoya Ghasemian et al. medRxiv. October 26, 2020.
  29. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Jeffrey Seow, et al. Nature microbiology. October 26, 2020. 
  30. Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. Percy Soto-Becerra Sr.,  Carlos Culquichicon,  Yamilee Hurtado-Roca,  Roger V Araujo-Castillo. medRxiv. October 14, 2020.
    https://doi.org/10.1101/2020.10.06.20208066DATAMEDICA.FISS, como medio de información, no necesariamente se adhiere a  algunas opiniones que se vierten en el presente trabajo, cuando este trabajo es una revisión preliminar y no ha sido certificado por revisión por pares, por lo tanto aún no deben utilizarse para guiar la práctica clínica. 
  31. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Antonio Méndez-Guerrero et al. Neurology. October 13, 2020. 
  32. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Antonio Méndez-Guerrero et al. American Academy of Neurology. October 13, 2020. 
  33. Genomic evidence for reinfection with SARS-CoV-2: a case study. Richard L Tillett, PhD, et al. October 12, 2020. 
  34. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. FaxiangChen, et al. ELSEVIER. October 11, 2020. 
  35. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. Juliana Cepelowicz Rajter, et al. medRxiv. June 10, 2020. 
    https://doi.org/10.1101/2020.06.06.20124461DATAMEDICA.FISS, como medio de información, no necesariamente se adhiere a algunas opiniones que se vierten en el presente trabajo, cuando este trabajo es una revisión preliminar y no ha sido certificado por revisión por pares, por lo tanto aún no deben utilizarse para guiar la práctica clínica. 
  36. A review on obesity as a risk factor for mortality in COVID-19 disease. Janeth Tenorio-Mucha, Yamilée Hurtado-Roca. Acta Médica Peruana. October 07, 2020. 
  37. Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells. Satish Sagar, et al. BioRxiv. September 16, 2020. 
  38. COVID-19 and the Path to Immunity. David S. Stephens, et al. JAMA Network. September 11, 2020. 
  39. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?. Hira Shakoor, et al. MATURITAS VOLUME 143, P1-9. January 01, 2021. 
  40. Trajectories of vital signs in patients with COVID-19. Marco A.F. Pimentel, et al. European Resuscitation Council. September 01, 2020. 
  41. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Tiong Kit Tan, et al. BioRxiv. August 31, 2020. 
  42. Designing of epitope-based vaccine from the conserved region of spike glycoprotein of SARS-CoV-2. Vidhu Agarwal, Pritish Varadwaj, Akhilesh Tiwari. BioRxiv. August 27, 2020. 
  43. Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. Lael M. Yonker, MD, et al. The Journal od Pediatrics. August 19, 2020. 
  44. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Sara Y Tartof, et al. Annals of Internal Medicine. August 12, 2020. 
  45. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Christiane Maria Prado Jeronimo, BSc, et al. Clinical Infectious Diseases. August 12, 2020. 
  46. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Takuya Sekine, et al. Cell. August 14, 2020.  
  47. Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app. Carole H Sudre, et al. June 16, 2020. medRxiv preprint doi: 
  48. Effect of anakinra in COVID-19. Emma J Kooistra, Nicole J B Waalders, Matthijs Kox, Peter Pickkers. THE LANCET. July 24, 2020. 
  49. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. Peter Horby, et al. NEJM. July 17, 2020. 
  50. Histopathology and genetic susceptibility in COVID‐19 pneumonia. Jan von der Thüsen, Menno van der Eerden. European Journal of Clinical Investigation. July 13, 2020. 
  51. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). W. Joost Wiersinga, MD, PhD; Andrew Rhodes, MD, PhD; Allen C. Cheng, MD, PhD.; et al. A Review JAMA. July 10, 2020.
  52. Placental Pathology in COVID-19. Elisheva D Shanes, et al. American Journal of Clinical Pathology, Volume 154, Issue 1. July, 2020. 
  53. Proning in Non-Intubated (PINI) in Times of COVID-19: Case Series and a Review. Vishesh Paul, MD, Shawn Patel, DO, Michelle Royse, APRN, Mazen Odish, MD, Atul Malhotra, MD, Seth Koenig, MD. Journal of Intensive Care Medicine 2020, Vol. 35(8) 818-824. July 7, 2020. 
  54. The COVID-19 Cytokine Storm; What We Know So Far. Dina Ragab, Haitham Salah Eldin, Mohamed Taeimah, Rasha Khattab and Ramy Salem. Frontiers in Immunology. Volume 11, article 1446. June 16, 2020. 
  55. Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app. View ORCID ProfileCarole H Sudre, et al. MedRxiv. June 16, 2020. 
  56. UNDERSTANDING IMMUNE RESPONSES TO SARS-COV-2. Charu Kaushic. Publication #28 Charu Kaushic. McMaster Immunology Research Center (MIRC). July 06, 2020. 
  57. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome A Cautionary Case Report. MD Jared RadbelEmail the author MD Jared Radbel, Navaneeth Narayanan, PharmD, MPHb, Pinki J. Bhatt, MD. CHEST 2020; 158(1):e15-e19. July, 2020. 
  58. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report: Mark J. Mulligan, et al. medRxiv. July 01, 2020. 
  59. A comparative observational study on Ivermectin- Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients: Abu Taiub Mohammed Mohiuddin Chowdhury; Shahbaz, Mohammad Shahbaz, Md Rezaul Karim; Islam, Jahirul; Dan, Guo; He, Shuixiang. June, 2020. 
  60. COVID-19 Lung Injury is Not High Altitude Pulmonary Edema: Andrew M. Luks, Luanne Freer, Colin K. Grissom, Scott E. McIntosh, Robert B. Schoene, Erik R. Swenson, and Peter H. Hackett.High Altitude Medicine & Biology.Jun 2020.192-193. 
  61. COVID-19 in 7780 Pediatric Patients: A Systematic Review. Ansel Hoang, Kevin Chorath, Axel Moreira, Mary Evans, Finn Burmeister-Morton, Fiona Burmeister, et al. University of Texas. THE LANCET. June 26, 2020. 
  62. Immunology of COVID-19: Current State of the Science. Nicolas Vabret, et al. Immunity 52. June 16, 2020. 
  63. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2: Carmen Riggioni, et al. EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. June 14, 2020. 
  64. Clinical manifestations of children with COVID‐19: A systematic review. Tiago H. de Souza MD, PhD; José A. Nadal MD, MSc;  Roberto J. N. Nogueira MD, PhD; Ricardo M. Pereira MD, PhD; Marcelo B. Brandão MD, PhD. Pediatric Pulmonology, Wiley. June 03, 2020. 
  65. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. Dr. Peter Horby. medRxiv. June 22, 2020. 
  66. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Wen Zhang, et al. Clinical Immunology. Volume 214, May 2020, 108393. 
  67. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Grifoni et al., 2020, Cell 181, 1–13. June 25, 2020 ©2020 Elsevier Inc.
  68. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Yun Feng, et al. American Journal of Respiratory and Critical Care Medicine, Volume 201, Issue 11. June 01, 2020. 
  69. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Leon Calya, Julian D. Drucea, Mike G. Cattona, David A. Jan, sbKylie M.Wagstaff. Antiviral Research. June 2020. 
  70. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities. Ahmad, Imtiaz et al. MedRxiv. May 22, 2020. 
  71. Preliminary Report of the Favipiravir Observational Study in Japan. Yohei Doi, Masashi Kondo, Akifumi Matsuyama, Masahiko Ando, Yachiyo Kuwatsuka, Takuma Ishihara. May 15, 2020. 
  72. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Prof Kunyu Yang, Yuhan Sheng, Prof Chaolin Huang, Prof Yang Jin, Nian Xiong, Ke Jiang, et al. May 29, 2020. 
  73. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Jianbo Tian, Prof Xianglin Yuan, Jun Xiao, Prof Qiang Zhong, Chunguang Yang, Bo Liu, et al. The Lancet Oncology. May 29, 2020. 
  74. Flatten the Curve! Modeling SARS-CoV-2/COVID-19 Growth in Germany on the County Level. Wieland Thomas. May 13, 2020. 
  75. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Yunlong Cao, Bin Su, Xianghua Guo, Chengfeng Qin, Ronghua Jin, X. Sunney Xie. May 17, 2020. 
  76. Characteristics and Outcomes of Patients Hospitalized for COVID-19 and Cardiac Disease in Northern Italy. Riccardo M Inciardi,et al. European Heart Journal 41(19):1821-1829. May 14, 2020. 
  77. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., and Wang, D.W. (2020). Sci China Life Sci 63. 15 May 2020. 
  78. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Ruijin Hospital of China. Wei Tang and col. Published 14 May 2020.
  79. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature Research. Gordon, D.E., Jang, G.M., Bouhaddou, M. et al. 30 April 2020.
  80. Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 (COVID-19). Actualización al 22 de abril de 2020. Elaborado por Fabiola Huaroto, Karen Huamán, Catherine Bonilla, Maricela Curisinche y Ericson Gutiérrez. Lima: Unidad de Análisis y Generación de Evidencias en Salud Pública. Instituto Nacional de Salud, abril de 2020. Serie Revision Rápida Nº 07-2020. 
  81. The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I. Yiwen Zhang, et al. May 24, 2020. 
  82. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Yeming Wang, et al. April 29, 2020. 
  83. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. Richard T. Eastman, Jacob S. Roth, Kyle R. Brimacombe, Anton Simeonov, Min Shen, Samarjit Patnaik, and Matthew D. Hall. ACS Central Science. May 4, 2020. 
  84. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Silvano Esposito, Silvana Noviello, Pasquale Pagliano. University of Salerno. Le Infezioni in Medicina, n. 2, 198-211, 2020. 
  85. COVID-19 pneumonia: ARDS or not?. Luciano Gattinoni, Davide Chiumello & Sandra Rossi. Critical Care volume 24, Article number: 154 (2020). April 16, 2020. 
  86. Vorläufiges Ergebnis und Schlussfolgerungen der COVID-19 Case-ClusterStudy (Gemeinde Gangelt). Dr. Hendrik Streeck, Dr. Gunther Hartmann,  Dr. Martin Exner, Dr. Matthias Schmid. April 09, 2020. 
  87. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19: Virginia D Schmith, Jie Zhou, Lauren RL Lohmer. April 26, 2020. 
  88. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Amit Kumar, Yuichi Kubota, Mikhail Chernov, Hidetoshi Kasuya. Medical Hypotheses 144 (2020) 109848. May 15, 2020. 
  89. Taype-Rondan A, Herrera-Añazco P, Málaga G. Sobre la escasa transparencia en los documentos técnicos para el tratamiento de pacientes con COVID-19 en Perú. Acta Med Peru. 2020;37(2):215-22. June 18, 2020. doi: